@conference{e822f4165c1445d39882dca51959d6ce,
title = "Individualized screening trial of innovative glioblastoma therapy (INSIGhT).",
author = "Alexander, \{Brian Michael\} and Lorenzo Trippa and Gaffey, \{Sarah C.\} and Isabel Arrillaga and Lee, \{Eudocia Quant\} and Tanguturi, \{Shyam Kumar\} and Ahluwalia, \{Manmeet Singh\} and Howard Colman and Evanthia Galanis and \{De Groot\}, \{John Frederick\} and Jan Drappatz and Lassman, \{Andrew B.\} and Nabors, \{Louis B.\} and Reardon, \{David A.\} and David Schiff and Welch, \{Mary Roberta\} and Ligon, \{Keith L.\} and Wen, \{Patrick Y.\}",
note = "TPS2079 Background: Patient with glioblastoma (GBM) with unmethylated MGMT promoters derive limited benefit from temozolomide (TMZ) and have dismal outcome. Prioritizing the numerous available therapies and biomarkers for late stage testing requires an efficient clinical testing platform. INSIGhT (NCT02977780) is a biomarker-based, Bayesian adaptively randomized, multi-arm phase II platform screening trial for patients with newly diagnosed GBM and unmethylated MGMT promoters.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2017",
month = may,
day = "30",
doi = "10.1200/JCO.2017.35.15\_SUPPL.TPS2079",
language = "American English",
}